Condition: Venous Thromboembolism · Cancer · Sponsor: Ottawa Hospital Research Institute
The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
This description comes directly from the study's public registry record.
Bashour Yazji · 613-737-8899 · byazji@ohri.ca
Always discuss trial participation with your own doctor first.
| Nova Scotia Health | Halifax, Nova Scotia, Canada | Recruiting |
| William Osler Health System | Brampton, Ontario, Canada | Recruiting |
| HHS - Juravinski Hospital | Hamilton, Ontario, Canada | Recruiting |
| Ottawa Hospital Research Institute- The Ottawa Hospital | Ottawa, Ontario, Canada | Recruiting |
| Sault Area Hospital | Sault Ste. Marie, Ontario, Canada | Recruiting |
| Niagara Health | St. Catharines, Ontario, Canada | Recruiting |
| Windsor Regional Hospital | Windsor, Ontario, Canada | Recruiting |
| CISSS Montérégie-Centre HOPITAL CHARLES LEMOYNE | Greenfield Park, Quebec, Canada | Recruiting |
| Centre Intégré de santé et de services sociaux de Chaudière-Appalaches | Lévis, Quebec, Canada | Recruiting |
| Jewish General Hospital | Montreal, Quebec, Canada | Recruiting |
| McGill University Health Center | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05029063